Latest News
Biogen Issues Q4 Community Statement on Spinraza
Bigoen has provided the below community statement on Spinraza. Dear Members of the SMA community, As we approach the two-year anniversary of the U.S. Food and Drug Administration’s (FDA) approval […]
Read More ›AveXis Issues Community Statement on BLA Acceptance
AveXis has provided the following community statement on the BLA submission and acceptance for their investigational therapy, AVXS-101 – now known as ZOLGENSMA®. Dear SMA Community, We are providing this […]
Read More ›Closing out 2018 with Good News: Virginia Adopts SMA to their Newborn Screening Panel, Arizona Moves Closer to Adopting SMA Newborn Screening and Illinois Medicaid Covers Spinraza Treatment
The SMA community has multiple victories to celebrate as the year comes to an end. Thank you to all our amazing families and advocates who have and continue to make […]
Read More ›Fall 2018 Issue of Compass Now Available
The fall 2018 issue of Compass is now available online. This issue of Compass covers the SMA Care Center Network and its goal of developing an evidence-based standard of care to […]
Read More ›Novartis Announces FDA Filing Acceptance and Priority Review for AVXS-101
Novartis today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for AVXS-101, now known as ZOLGENSMA® (onasemnogene abeparvovec-xxxx)1, an investigational gene […]
Read More ›Register for Cure SMA’s Webinar on SMA Treatments and Clinical Trials
On Wednesday, December 12th, at 12:00pm CST (10:00am PST/11:00am MST/1:00pm EST) Cure SMA will hold a webinar updating the community on the latest information on SMA treatments and trials. Topics […]
Read More ›